Increasing inclusion and equity for Black women in breast cancer clinical trials.

IF 1.1 Q4 ONCOLOGY Clinical Advances in Hematology & Oncology Pub Date : 2024-05-01
Ammanuel Taye, Ahmed Elkhanany, Erica Stringer-Reasor
{"title":"Increasing inclusion and equity for Black women in breast cancer clinical trials.","authors":"Ammanuel Taye, Ahmed Elkhanany, Erica Stringer-Reasor","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Black women diagnosed with breast cancer experience a disproportionately high mortality rate. The disparity in outcomes between Black and White women is multifactorial, with a large portion attributed to lower participation of minorities in clinical trials. The lack of diversity in clinical trials continues to both reflect and contribute to health care inequities, limiting the generalizability of research findings. In addition, women who do not enroll in clinical trials miss out on the standard-of-care or often better patient care provided in these trials. Barriers to enrolling diverse populations encompass system-, provider-, and patient-level barriers. Identifying these barriers and providing actionable solutions are key to bolstering enrollment in clinical trials and ultimately eliminating cancer disparities. This review elucidates the barriers to clinical trial participation in Black women diagnosed with breast cancer and discusses ways to overcome these challenges.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"22 4","pages":"175-182"},"PeriodicalIF":1.1000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Advances in Hematology & Oncology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Black women diagnosed with breast cancer experience a disproportionately high mortality rate. The disparity in outcomes between Black and White women is multifactorial, with a large portion attributed to lower participation of minorities in clinical trials. The lack of diversity in clinical trials continues to both reflect and contribute to health care inequities, limiting the generalizability of research findings. In addition, women who do not enroll in clinical trials miss out on the standard-of-care or often better patient care provided in these trials. Barriers to enrolling diverse populations encompass system-, provider-, and patient-level barriers. Identifying these barriers and providing actionable solutions are key to bolstering enrollment in clinical trials and ultimately eliminating cancer disparities. This review elucidates the barriers to clinical trial participation in Black women diagnosed with breast cancer and discusses ways to overcome these challenges.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
提高黑人妇女在乳腺癌临床试验中的包容性和公平性。
被诊断出患有乳腺癌的黑人妇女的死亡率高得不成比例。黑人妇女和白人妇女在治疗结果上的差距是多因素造成的,其中很大一部分原因是少数族裔参与临床试验的比例较低。临床试验缺乏多样性继续反映并助长了医疗保健的不平等,限制了研究结果的推广性。此外,没有参加临床试验的女性也错过了这些试验提供的标准护理或通常更好的患者护理。让不同人群参与临床试验的障碍包括系统、提供者和患者层面的障碍。识别这些障碍并提供可行的解决方案是提高临床试验入组率并最终消除癌症差异的关键。本综述阐明了确诊患有乳腺癌的黑人女性参与临床试验的障碍,并讨论了克服这些挑战的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.10
自引率
0.00%
发文量
99
期刊介绍: Clinical Advances in Hematology & Oncology (CAH&O) is a monthly peer-reviewed journal reaching more than 27,000 hematology and oncology clinicians. CAH&O provides editorial content encompassing a wide array of topics relevant and useful to the fields of oncology and hematology, both separately and together. Content is directed by the strong input of today’s top thought leaders in hematology & oncology, including feature-length review articles, monthly columns consisting of engaging interviews with experts on current issues in solid tumor oncology, hematologic malignancies, hematologic disorders, drug development, and clinical case studies with expert commentary. CAH&O also publishes industry-supported meeting highlights, clinical roundtable monographs, and clinical review supplements.
期刊最新文献
Recombinant ADAMTS13 concentrate in thrombotic thrombocytopenic purpura. Should ponatinib be the standard-of-care tyrosine kinase inhibitor in Ph+ ALL? Does combination menopausal hormone therapy increase the risk of breast cancer? Tackling the cancer drug shortage. Targeted therapy in prostate cancer: beyond PSMA.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1